Triple HIV combo for children approved under PEPFAR
The first triple-combination drug for treating HIV-infected children under the age of 12 years receives tentative approval from FDA Aug. 13 as part of the President's Emergency Plan for AIDS Relief. Approved as a 505 (b)(2) NDA, the twice-daily dissolvable tablet from Cipla combines lamivudine (GlaxoSmithKline's Epivir), stavudine (Bristol-Myers Squibb's Zerit) and nevirapine (Boehringer Ingelheim's Viramune). The tablet formulation makes the drug suitable for use in regions with high temperatures and high humidity and enables treatment of children weighing as little as 5 kg, Division of Antiviral Products Director Debra Birnkrant notes. FDA also gives tentative approval under PEPFAR for nevirapine tablets to be used with antiretrovirals for treating HIV-1...
You may also be interested in...
MIAMI BEACH, Fla. - Ira Magaziner, the chairman of the Clinton Foundation HIV/AIDS Initiative, used a speaking engagement to deliver a pitch to the generics industry: come to developing countries to make a lot of money and help people gain access to low-cost drugs
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.